Robert Janknegt¹*, Mark Reinders¹ and Rutger Bianchi²

¹Hospital Pharmacist, Zuyderland Medical Centre, The Netherlands
²Internist, Endocrinologist, Zuyderland Medical Centre, The Netherlands

*Corresponding Author: Robert Janknegt, Hospital Pharmacist, Zuyderland Medical Centre, The Netherlands.

Received: February 26, 2021; Published:

Abstract

Objectives: The increasing number of antidiabetic drugs makes it almost impossible to have sufficient knowledge of each individual medicine and device, especially for general practitioners.

Reducing the number of different antidiabetics based on rational criteria, allows physicians and pharmacists to build experience with a more limited set of medicines and to optimise patient information.

Methods: In this study SGLTs are compared by means of the SOJA method.

The following selection criteria were applied: ease of use, available dosage forms, clinical efficacy, documented effects on clinical endpoints, safety, tolerability, drug interactions and documentation.

Results: Some differences in scores were found between canagliflozin, dapagliflozin, empagliflozin and ertugliflozin. Ertugliflozin showed the lowest score, mostly because of its more limited clinical evidence and documentation. Empagliflozin and dapagliflozin showed the highest scores. These medicines are well documented concerning clinical endpoints, including heart failure and safety.

Acquisition cost was not taken into account, because this varies with time. In practice acquisition cost is of course an important selection criterion, especially because there are no major differences between the medicines from a clinical perspective. Exclusion of this criterion also makes this comparison more internationally applicable.

Conclusions: Empagliflozin and dapagliflozin showed the highest scores, mainly because of their documented effects on clinically relevant endpoints and safety.

Keywords: Dapagliflozin; Empagliflozin; SOJA Method

References

1. Lebovitz HE. “Oral therapies for diabetic hyperglycemia”. Endocrinology and Metabolism Clinics of North America 30 (2001): 909-933.
2. Rosenstock J. “Management of type 2 diabetes mellitus in the elderly: special considerations”. Drugs Aging1 (2001): 31-44.
3. Davis TM., et al. “Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29”. Archives of Internal Medicine 159 (1999): 1097-1103.
4. Pratley RE., et al. “Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control”. Current Pharmaceutical Design 7 (2001): 1375-1397.
5. Bailey CJ and Turner RC. “Metformin”. The New England Journal of Medicine 334 (1996): 574-579.
6. Dunn CJ and Peters DH. “Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus”. Drugs 49 (1995): 721-749.
7. Mehnert H. “Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance”. Experimental and Clinical Endocrinology and Diabetes 109 (2001): S259-264.
8. Palmer KJ and Brogden RN. “Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus”. Drugs 46 (1993): 92-125.
9. Muller G., et al. “Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas”. Diabetes Research and Clinical Practice 28 (1995): S115-137.
10. Langtry HD., et al. “Glimepiride. A review of its use in the management of type 2 diabetes mellitus”. Drugs 55 (1998): 563-584.
11. Davies MJ. “Insulin secretagogues”. Current Medical Research and Opinion 18 (2002): s22-30.
12. Diamant M and Heine RJ. “Thiazolidinediones in type 2 diabetes mellitus”. Current Clinical Evidence Drugs 63 (2003): 1373-1405.
13. Janknegt R and Steenhoek A. “The System of Objectified Judgement Analysis. A tool in rational drug selection for formulary purposes”. Drugs 53 (1997): 550-562.
14. Lee JD., et al. “Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine)”. Current Medical Research and Opinion 20 (2004): 765-772.
15. UK Prospective Diabetes Study (UKPDS) Group. “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)”. Lancet 352 (1998): 837-853.
16. Manley S. “Haemoglobin A1c--a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS)”. Clinical Chemistry and Laboratory Medicine 41 (2003): 1182-1190.
17. Stratton IM., et al. “Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study”. BMJ 321 (2000): 405-412.
18. Adler AI., et al. “Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47)”. American Heart Journal 138 (1999): S353-359.
19. Stevens RJ., et al. “Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66”. Diabetes Care 27 (2004): 201-207.
20. McCulloch DK. “Treatment of blood glucose in type 2 diabetes mellitus”. American Family Physician1 (2009): 29-36.
21. Goldstein BJ. “Differentiating members of the thiazolidinedione class: a focus on efficacy”. Diabetes/Metabolism Research and Reviews 18 (2002): S16-22.
22. Goldstein BJ., et al. “Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?”. Current Medical Research and Opinion3 (2003): 192-199.
23. Flier JS and Mantzoros C. “Insulin resistance: definition and clinical spectrum”.
24. Scheen AJ. “Management of the metabolic syndrome”. Minerva Endocrinology 29 (2004): 31-45.
25. Ovalle F and Bell DS. “Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes”. Diabetes Care 27 (2004): 2585-2589.
26. Smith SA., et al. “Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes”. The Journal of Clinical Endocrinology and Metabolism 89 (2004): 6048-6053.
27. Mauvais-Jarvis F., et al. “Therapeutic perspectives for type 2 diabetes mellitus: molecular and clinical insights”. Diabetes Metabolism 27 (2001): 415-423.
28. Storgaard H., et al. “Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis”. PLoS One 11 (2016): e0166125.
29. Shyangdan DS., et al. “SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis”. BMJ Open 6 (2016): e009417.
30. McNeill AM., et al. “Ertugliflozin Compared to Other Anti-hyperglycemic Agents asMonotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta Analysis”. Diabetes Therapy2 (2019): 473-491.
31. Zhang YJ., et al. “Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials”. Medicine (Baltimore) 97 (2018): e12843.
32. Zhong X., et al. “Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis”. European Journal of Clinical Pharmacology 72 (2016): 655-663.
33. Mearns ES., et al. “Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis”. Diabetic Medicine 32 (2015): 1530-1540.
34. Mearns ES., et al. “Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis”. PLoS One 10 (2015): e0125879.
35. Mudaliar S., et al. “Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin”. Diabetes Technology and Therapeutics 16 (2014): 137-144.
36. Merovci A., et al. “Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males”. The Journal of Clinical Endocrinology and Metabolism 101 (2016): 1249-1256.
37. Leiter LA., et al. “Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study”. Diabetes Care 38 (2015): 355-364.
38. Traina S., et al. “The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes”. Postgraduate Medicine3 (2014): 7-15.
39. Wilding J., et al. “Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up”. Primary Care Diabetes (2017): pii:S1751-9918 (17)30072-4.
40. Bolinder J., et al. “Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin”. The Journal of Clinical Endocrinology and Metabolism 97 (2012): 1020-1031.
41. Rosenstock J., et al. “Effects of dapagliflozin, an SGLT2 inhibitor, on HbA (1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy”. Diabetes Care 35 (2012): 1473-1478.
42. Bolinder J., et al. “Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin”. Diabetes, Obesity and Metabolism 16 (2014): 159-169.
43. Matthaei S., et al. “Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial”. Diabetes Care 38 (2015): 365-372.
44. Sjöström CD., et al. “Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels”. Diabetes, Obesity and Metabolism 17 (2015): 809-812.
45. Wilding J., et al. “Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study”. Diabetes Therapy 7 (2016): 695-711.
46. Scheerer MF., et al. “Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study”. Diabetes Metabolism 9 (2016): 337-345.
47. Kostev K., et al. “Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study”. Journal of Diabetes Science and Technology 11 (2017): 590-596.
48. Kovacs CS., et al. “Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial”. Diabetes, Obesity and Metabolism 16 (2014): 147-158.
49. Rosenstock J., et al. “Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes”. Diabetes Care 37 (2014): 1815-1823.
50. Neeland IJ., et al. “Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus”. Diabetes and Vascular Disease Research 13 (2016): 119-126.
51. Shiba T., et al. “Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials”. Diabetes Research and Clinical Practice 131 (2017): 169-178.
52. Camacho P., et al. “Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus”. Drugs Aging 17 (2000): 463-476.
53. Holman R. “The UKPDS: implications for the dyslipidaemic patient”. Acta Diabetology 38 (2001): S9-14.
54. Adler AI., et al. “UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes”. Diabetes Care 25 (2002): 894-899.
55. Song SH and Brown PM. “Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications”. Diabetic Medicine 21 (2004): 238-245.
56. Inagaki N., et al. “Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus”. Advances in Therapy 32 (2015): 1085-1103.
57. Bays HE., et al. “Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels”. Journal of Clinical Lipidology 11 (2017): 450-458.e1.
58. Fadini GP., et al. “Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial”. Cardiovascular Diabetology 16 (2017): 42.
59. Hayashi T., et al. “Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin”. Cardiovascular Diabetology 16 (2017): 8.
60. Briand F., et al. “Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism”. Diabetes 65 (2016): 2032-2038.
61. Weir MR., et al. “Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus”. Journal of Clinical Hypertension (Greenwich) 16 (2014): 875-882.
62. Cefalu WT., et al. “Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes”. Diabetologia 58 (2015): 1183-1187.
63. Guthrie RM. “Practice pearl: the effect of canagliflozin on HbA1c and blood pressure in patients with type 2 diabetes mellitus”. Postgraduate Medicine 127 (2016): 783-785.
64. Lefebvre P., et al. “Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study”. Current Medical Research and Opinion 32 (2016): 1151-1159.
65. Townsend RR., et al. “Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension”. Journal of Clinical Hypertension (Greenwich) 18 (2016): 43-52.
66. Pfeifer M., et al. “Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis”. Cardiovascular Diabetology 16 (2017): 29.
67. Kohan DE., et al. “Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control”. Kidney International 85 (2014): 962-971.
68. Sjöström CD., et al. “Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels”. Diabetes, Obesity and Metabolism 17 (2015): 809-812.
69. Sjöström CD., et al. “Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes”. Diabetes and Vascular Disease Research 12 (2015): 352-358.
70. Weber MA., et al. “Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study”. Lancet Diabetes and Endocrinology 4 (2016): 211-220.
71. Weber MA., et al. “Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade”. Blood Press 25 (2016): 93-103.
72. Tikkanen I., et al. “Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension”. Diabetes Care 38 (2015): 420-428.
73. Chilton R., et al. “Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes”. Diabetes, Obesity and Metabolism 17 (2015): 1180-1193.
74. Mancia G., et al. “Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication”. Hypertension 68 (2016): 1355-1364.
75. Rosenstock J., et al. “Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)”. Diabetes, Obesity and Metabolism3 (2018): 520-529.
76. Amin NB., et al. “Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension”. Diabetes, Obesity and Metabolism 8 (2015): 805-808.
77. Booth GL., et al. “Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study”. Lancet 368 (2006): 29-36.
78. Kelly TN., et al. “Systematic review: Glucose control and cardiovascular disease in type 2 diabetes”. Annals of Internal Medicine 151 (2009): 394-403.
79. Neal B., et al. “Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes”. The New England Journal of Medicine 377 (2017): 644-657.
80. Wiviott SD., et al. “Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes”. The New England Journal of Medicine4 (2019): 347-357.
81. Zinman B., et al. “Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes”. The New England Journal of Medicine 373 (2015): 2117-2128.
82. Cannon CP., et al. “Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes”. The New England Journal of Medicine (2020).
83. McMurray JJV., et al. “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction”. The New England Journal of Medicine 381 (2019): 1995-2008.
84. Petrie MC., et al. “Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes”. JAMA 323 (2020): 1353-1368.
85. Lee G., et al. “Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis”. PLoS One 12 (2017): e0177646.
86. Salsali A., et al. “Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials”. Diabetes, Obesity and Metabolism 18 (2016): 1034-1040.
87. Zinman B., et al. “Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk”. Stroke 48 (2017): 1218-1225.
88. Fitchett D., et al. “Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial”. European Heart Journal 37 (2016): 1526-1534.
89. Packer M., et al. “Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure”. The New England Journal of Medicine 383 (2020): 1413-1424.
90. Naci H., et al. “Preventing cardiovascular events with empagliflozin: at what cost?”. Lancet Diabetes and Endocrinology 3 (2015): 931.
91. Packer M., et al. “Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.Lower Risk of Cardiovascular Events and All-cause Mortality in Type 2 Diabetes Patients (CVD-REAL Nordic): a multinational observational study”. Diabetes, Obesity and Metabolism (2017).
92. Birkeland KI., et al. “Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis”. Lancet Diabetes and Endocrinology (2017): pii: S2213-8587 (17)30258-9.
93. Adler AI., et al. “Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)”. Kidney International 63 (2003): 225-232.
94. Heerspink HJ., et al. “Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects”. Journal of the American Society of Nephrology 28 (2017): 368-375.
95. Perkovic V., et al. “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy”. The New England Journal of Medicine 380 (2019): 2295-2306.
96. Heerspink HJL., et al. “Dapagliflozin in Patients with Chronic Kidney Disease”. The New England Journal of Medicine 383 (2020): 1436-1446.
97. Cherney DZI., et al. “Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial”. Lancet Diabetes and Endocrinology 5 (2017): 610-621.
98. Wanner C., et al. “Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes”. The New England Journal of Medicine 375 (2016): 323-334.
99. Neuen BL., et al. “SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis”. Lancet Diabetes and Endocrinology 7 (2019): 845-854.
100. Bilezikian JP., et al. “Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin”. The Journal of Clinical Endocrinology and Metabolism 101 (2016): 44-51.
101. Watts NB., et al. “Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus”. The Journal of Clinical Endocrinology and Metabolism 101 (2016): 157-166.
102. Ljunggren Ö., et al. “Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin”. Diabetes, Obesity and Metabolism 14 (2012): 990-999.
103. Fioretto P., et al. “Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies”. Drugs Aging 33 (2016): 511-522.
104. Kohler S., et al. “Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes”. Clinical Therapy 38 (2016): 1299-1313.
105. “SPC canagliflozin”.
106. “SPC dapagliflozin”.
107. “SPC empagliflozin”.
108. “SPC ertugliflozin”.
109. Azharuddin M., et al. “Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials”. Diabetes Research and Clinical Practice 146 (2018): 180-190.
110. Ruanpeng D., et al. “Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis”. Diabetes Metabolism6 (2017).
111. Tang HL., et al. “Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials”. Diabetes, Obesity and Metabolism 18 (2016): 1199-1206.
112. Qiu R., et al. “Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes”. Diabetes Therapy 7 (2016): 659-678.
113. Fioretto P., et al. “Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus”. Cardiovascular Diabetology 14 (2015): 142.
114. Kohler S., et al. “Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes”. Clinical Therapy 38 (2016): 1299-1313.
115. Kohler S., et al. “Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials”. Advances in Therapy 34 (2017): 1707-1726.
116. Davies MJ., et al. “Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data”. Cardiovascular Diabetology 16 (2017): 40.
117. Xiong W., et al. “Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials”. Medicine (Baltimore) 95 (2016): e5473.
118. Plosker GL. “Canagliflozin: a review of its use in patients with type 2 diabetes mellitus”. Drugs 74 (2014): 807-824.
119. Li D., et al. “Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials”. Diabetes Metabolism 44 (2018): 410-414.
120. Ryan PB., et al. “Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)”. Diabetes, Obesity and Metabolism 20 (2018): 2585-2597.
121. Tang H., et al. “SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials”. Diabetologia (2017).
122. Puckrin R., et al. “SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials”. Acta Diabetology 55 (2018): 503-514.
123. Li D., et al. “Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials”. Diabetes, Obesity and Metabolism 19 (2017): 348-355.
124. Zaccardi F., et al. “Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis”. Diabetes, Obesity and Metabolism 18 (2016): 783-794.
125. Bundhun PK and Huang F. “Adverse Drug Events Associated with sitagliptin Versus canagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Comparison Through a Meta-Analysis”. Diabetes Therapy 9 (2018): 1883-1895.
126. Meng Q., et al. “Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials”. Journal of Diabetes Investigation 7 (2016): 359-365.
127. Dawra VK., et al. “Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects”. Clinical Therapy 40 (2018): 1538-1547.
128. Zelniker TA., et al. “SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials”. Lancet 393 (2019): 31-39.

Citation

Citation: Robert Janknegt., et al. “SGLT-2 Inhibitors: Drug Selection by Means of the System of Objectified Judgement Analysis Method". Acta Scientific Pharmaceutical Sciences 5.7 (2020): 91-112.

Copyright

Copyright: © 2020 Robert Janknegt., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.